On April 1, 2021, biopharmaceutical company AbbVie shared that new data is available from the Phase 3 SELECT-PsA 1 clinical trial. The 24-week results follow the impact of RINVOQ (upadacitinib)…
A study published in Physician's Weekly investigated the visual outcomes, clinical features, and treatment of individuals with occlusive retinal vasculitis (ORV), a condition that is characterized by inflammation in the vessels of…
Recent results of a Turkish trial have demonstrated the need for further research into IFN-gamma as a treatment for Friedreich's ataxia (FA). This study showed that the therapy resulted in…
During the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, researchers presented data from the Phase 2 OVARIO clinical trial. According to Cancer Network, the trial evaluated…
Pamrevlumab is a first-in-class antibody that treats Duchenne muscular dystrophy (DMD) by inhibiting the effects and activity of connective tissue disorder growth factor (CTGF). It is being developed by FibroGen,…
A new study published in JAMA Oncology has found that of all patients who have had cancer spread to their bones and started treatment, 2,8% have developed osteonecrosis within their jaw, also…
From February 25-27, the Americas Committee for Treatment and Research in Multiple Sclerosis will run its ACRTIMS Forum 2021, according to BioSpace. At this forum, Clene Inc. will present interim…
A Phase 3 study of upadacitinib, an ulcerative colitis treatment, met both its primary and secondary endpoints, according to an announcement from AbbVie. The trial, titled U-ACCOMPLISH, saw a third…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
